一分钟看懂
这是一项关于白血病的不适用研究，登记的药物或干预包括TBF regimen，当前状态为招募中。登记地点显示中国北京有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
TBF regimen · 不适用
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University People's Hospital · 北京
公开的入选条件
- * Age ≥ 18 years, any sex/gender.
- * Confirmed diagnosis of chronic myelomonocytic leukemia (CMML) according to the 2022 WHO classification.
- * Intermediate-2 or high-risk CMML based on CPSS or CPSS-mol score, and planned to receive allo-HSCT.
- * Has a suitable hematopoietic stem cell donor:
- * For haploidentical donor: at least 5/10 HLA match at HLA-A, -B, -C, -DQB1, and -DRB1.
- * For unrelated donor: at least 9/10 HLA match at the same five loci.
- * For matched sibling donor: 10/10 HLA match at the same five loci.
- * Hematopoietic cell transplantation comorbidity index (HCT-CI) ≤ 2, with generally good health and no significant organ abnormalities or major comorbidities.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07588594；登记信息更新于 2026-09-15。